Metabolic · Phase 3 · Site operations

Obesity & Diabetes Trial Recruitment: WCR 27-Screening Case

A Phase 3 obesity and diabetes study paired early patient engagement with additional staffing before activation.

Study experience and results: Wellness Clinical Research. Perspective by Wellness Global Research.

WCR-reported study results

27Screened in month one after activation
13Subsequently randomized
Within 1 weekActivation to first screening

Match patient access with people

WCR reports adding full-time team capacity and making new hires before the study started. That preparation ran alongside engagement with practice patients. It addressed both sides of the recruitment plan: access to potential participants and people available to support their screening activity.

Read the timing carefully

Twenty-seven participants were screened within the first month after activation. Thirteen subsequently randomized, with approximately one month between screening and randomization. These are different intervals. The source does not classify the remaining screened participants’ outcomes, and it does not say that all 13 randomized during the first month after activation.

Plan the work around the recruitment estimate

A larger candidate pipeline creates demands for records, appointments, procedures, and follow-up. WGR helps sponsors and physician partners assess those demands against available staffing and visit capacity. Coordinating outside assessments, nutrition, and lifestyle support is part of making the recruitment plan workable.

Apply the questions to your protocol

Connect the experience
to the study ahead.

Discuss investigator fit, patient access, study resources, and the support model with WGR’s central team.

Discuss your studyReview sponsor capabilities

Original source

Obesity & Diabetes Trial Recruitment: WCR 27-Screening Case at Wellness Clinical Research

WCR is WGR’s sister company. These are WCR’s reported study outcomes, presented here with original WGR commentary.

Related experience

Keep exploring.